Improving Medication Adherence in Adults with Pulmonary Arterial Hypertension Using Telemedicine Support A Multicenter Study with Remote Patient Guidance

What this Trial Is About

Pulmonary arterial hypertension PAH is a serious and progressive condition that often leads to high rates of hospitalization and right heart failure. This research aims to evaluate whether a structured telemedicine program can improve medication adherence and overall clinical outcomes in patients with PAH who are on stable oral therapies. The study focuses on addressing the ongoing challenge of poor treatment adherence despite advances in available medications. Participants in this randomized clinical trial will be divided into two groups one receiving biweekly teleconsultations for six months and the other receiving standard clinical care without additional remote support. The telemedicine intervention includes patient education, monitoring of medication adherence, side effect management, and motivational support, all delivered by trained healthcare professionals without changing the prescribed medication regimen. During the study, participants will be monitored through baseline and 24-week assessments, including medication adherence measured by the Martn-Bayarre-Grau scale, functional classification, six-minute walk test, brain natriuretic peptide levels, risk stratification using COMPERA 2.0 and REVEAL Lite tools, hospitalizations, mortality, and quality of life via the CAMPHOR questionnaire. The total study duration for each participant is 24 weeks, with close follow-up to assess the impact of the telemedicine support on treatment adherence and health outcomes.

imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce